Innovation

Modulation of Epidermal Growth Factor Heterodimer Activity

University of North Carolina at Chapel Hill
posted on 08/11/2006

A method of screening for compounds which bind to and modulate the activity and/or formation of pathological EGFR-ERBB heterodimers without inhibiting normal receptor function.


Innovation Details
 

Detailed Description

The formation of EGFR homodimers and ERBB family heterodimers are critical to normal receptor function. However, EGFR-ERBB heterodimers are associated with cell transformation and tumor growth. Current inhibitors of ERBB or EGF target these pathways non-specifically, leading to undersirable side effects. This method allows for targeting screening of compounds that inhibit only EGFR-ERBB heterodimers.

File Number: 04-0056 

Other Information:

Testing
pre-clinical


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Scott Forrest at University of North Carolina at Chapel Hill for more information.

request more info
People

Case Manager:

Icon_avatar Scott Forrest

Innovations (21)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

4,057 members 12,269 innovations 109 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...